Drug Database
Back to search

Italy· 045445032

MAVIRET*28 bust orale grat 50 mg + 20 mg

A glecaprevir and pibrentasvir product containing glecaprevir/pibrentasvir, registered in Italy by ABBVIE DEUTSCHLAND GmbH&CO.KG, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.

Reimbursed in Italy (AIFA class A)ATC J05AP57

Checked against the register on

Informational only — not a medical device.

SOURCE REGISTER · ITPublic registernormalisedMAVIRET*28 bust orale grat 50 mg + 20…ATCJ05AP57REGISTER NO.045445032PACKS LISTED1CHECKEDJune 4, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about glecaprevir/pibrentasvirAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Glecaprevir and pibrentasvir is registered in 15 of 19 countries.

Countries holding a registration under ATC J05AP57 (glecaprevir and pibrentasvir), each read from that country’s own register.

  • This record: Italy
  • 10 of them publish a price we can compare per daily dose
Search glecaprevir and pibrentasvir products by name

Glecaprevir and pibrentasvir · ATC J05AP57

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Active substance
Glecaprevir/pibrentasvir
Manufacturer
ABBVIE DEUTSCHLAND GmbH&CO.KG
Country
Italy (IT)
ATC code
J05AP57
ATC class
Glecaprevir and pibrentasvir
Reimbursed
Yes
Last checked
June 4, 2026

Packs & prices · 1

1 priced
  • aic
    045445032
    MAVIRET*28 bust orale grat 50 mg + 20 mg
    EUR 3475.46

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same class

Other records under J05AP57

Glecaprevir and pibrentasvir, as other registers publish it.

All glecaprevir and pibrentasvir products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/bd73da60-01e4-40e1-b312-b5c063ed34e4
GET /v1/drugs/bd73da60-01e4-40e1-b312-b5c063ed34e4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "price": 3475.46,
  "source": "aifa",
  "currency": "EUR",
  "strength": "GLECAPREVIR+PIBRENTASVIR 50MG+20MG 28 UNITA' USO ORALE",
  "substance": "Glecaprevir/pibrentasvir",
  "equivalence_group": "MJP",
  "transparency_flag": null
}
API referenceMCP serverPlans

See everything about glecaprevir and pibrentasvir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console